NeuroPace Q4 rev $26.6M (+24%), FY25 rev $100M (+25%); guides FY26 $98-100M

NeuroPace Inc

Q4 2025 revenue $26.6M (+24% YoY); RNS System revenue $22.4M (+26% YoY); gross margin 77.4%.
Full year 2025 revenue $100.0M (+25% YoY); net loss ($2.7M) Q4; Adj. EBITDA ($5.0M) FY25.
Submitted PMA-S to FDA for IGE indication expansion; NAUTILUS trial showed 77% median seizure reduction.
Reiterated FY26 guidance: total rev $98-100M (20-22% RNS growth); Adj. EBITDA ($9-10M).
DIXI Medical partnership ended Dec 31, 2025; discontinued ops reporting to begin Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.